Avedro's Photrexa Products and KXL System, First FDA Approved Cross-Linking Procedures Are Performed on Patients in the U.S. with Progressive Keratoconus
Corneal collagen cross-linking with Avedro's Photrexa Viscous, Photrexa and the KXL system is the first and only cross-linking therapy approved by the FDA. Patients and families should contact Kornmehl Laser Eye Associates to schedule a consultation to see if corneal collagen cross-linking is best for them.
- (1888PressRelease) October 05, 2016 - Wellesley, Massachusetts, USA - Kornmehl Laser Eye Associates, today announced that it is offering the first and only cross-linking treatment approved by the U.S. Food and Drug Administration (FDA) for keratoconus and corneal ectasia following refractive surgery, two progressive and sight-threatening eye conditions that, combined, affect more than 170,000 Americans. The newly approved treatment- Avedro's Photrexa products and KXL System- halts disease progression by making the cornea stronger. Corneal transplant is the only other approved treatment alternative to stopping disease progression.
In keratoconus patients, the typically round, dome-shaped cornea progressively thins and weakens, causing the development of a cone-like bulge that produces optical irregularities that affect vision. A rare condition, keratoconus typically appears in individuals who are in their late teens or early twenties. Early symptoms include blurring or distortion of vision or increased sensitivity to light. Corneal ectasia, also marked by progressive corneal steepening and thinning, is a rare but serious complication resulting from vision correction procedures- such as laser-assisted-in-situ keratomileusis (LASIK) and photorefractive keratectomy (PRK), and is associated with worsening of vision.
Ernest W. Kornmehl, M.D.,F.A.C.S., Medical Director, Kornmehl Laser Eye Associates and Clinical Instructor, Harvard Medical School states "patients who demonstrate progressive keratoconus should be treated with collagen cross-linking immediately. Managing these patients with contact lenses is completely inappropriate. Collagen cross-linking will significantly reduce the number of corneal transplants performed in the U.S."
"Avedro's product launch has been highly anticipated by the keratoconus community as patients can now receive the only FDA-approved cross-linking treatment available in the U.S.," said Mary Prudden, Executive Director for the National Keratoconus Foundation. "The timing is ideal as we prepare for the first World Keratoconus Day taking place on November 10th."
Contact:
Ellen Hildreth
Kornmehl Laser Eye Associates
(877) 870-2010
www.visionboston.com
info ( @ ) visionboston dot com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam